CN105166935B - 一种含有维生素d3的液体制剂及其制备方法 - Google Patents
一种含有维生素d3的液体制剂及其制备方法 Download PDFInfo
- Publication number
- CN105166935B CN105166935B CN201510547248.4A CN201510547248A CN105166935B CN 105166935 B CN105166935 B CN 105166935B CN 201510547248 A CN201510547248 A CN 201510547248A CN 105166935 B CN105166935 B CN 105166935B
- Authority
- CN
- China
- Prior art keywords
- vitamine
- parts
- solution
- liquid
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011782 vitamin Substances 0.000 title claims abstract description 117
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 title claims abstract description 113
- 239000007788 liquid Substances 0.000 title claims abstract description 98
- 238000002360 preparation method Methods 0.000 title claims abstract description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 48
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 27
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 27
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 24
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 16
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 8
- 108010011485 Aspartame Proteins 0.000 claims abstract description 8
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 8
- 229960003438 aspartame Drugs 0.000 claims abstract description 8
- 235000010357 aspartame Nutrition 0.000 claims abstract description 8
- 239000000605 aspartame Substances 0.000 claims abstract description 8
- 239000001259 polydextrose Substances 0.000 claims abstract description 8
- 229940035035 polydextrose Drugs 0.000 claims abstract description 8
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 8
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 8
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 8
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 55
- 239000012153 distilled water Substances 0.000 claims description 23
- 108010010803 Gelatin Proteins 0.000 claims description 21
- 229920000159 gelatin Polymers 0.000 claims description 21
- 239000008273 gelatin Substances 0.000 claims description 21
- 235000019322 gelatine Nutrition 0.000 claims description 21
- 235000011852 gelatine desserts Nutrition 0.000 claims description 21
- 239000011259 mixed solution Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 230000001954 sterilising effect Effects 0.000 claims description 17
- 238000007689 inspection Methods 0.000 claims description 14
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 7
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000003760 magnetic stirring Methods 0.000 claims description 7
- 229940098462 oral drops Drugs 0.000 claims description 7
- 238000012797 qualification Methods 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 235000011837 pasties Nutrition 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 9
- 239000000047 product Substances 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000036737 immune function Effects 0.000 abstract description 4
- 208000019505 Deglutition disease Diseases 0.000 abstract description 3
- 230000003185 calcium uptake Effects 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000012085 test solution Substances 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 8
- 229940100688 oral solution Drugs 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000283977 Oryctolagus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000276435 Gadus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- -1 warp After sunlight Chemical compound 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicinal Preparation (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | n | 脾脏相对重 | 胸腺相对重 |
对照组 | 12 | 5.52±0.95 | 3.64±0.23 |
低剂量组 | 12 | 5.49±1.30 | 3.72±1.15 |
中剂量组 | 12 | 5.86±1.19 | 4.18±0.46* |
高剂量组 | 12 | 5.18±0.24 | 4.02±0.58* |
组别 | N | IgM-PFC/全脾 |
溶剂对照 | 12 | 27.581±1.80 |
低剂量组 | 12 | 25.657±1.62 |
中剂量组 | 12 | 42.897±1.84* |
高剂量组 | 12 | 58.712±1.38** |
组别 | N | 足跖增加厚度(mm) |
溶剂对照 | 12 | 0.42±0.18 |
低剂量组 | 12 | 0.58±0.22 |
中剂量组 | 12 | 0.69±0.27* |
高剂量组 | 12 | 0.65±0.23 |
组别 | n | K | α |
对照组 | 12 | 0.0152±0.0058 | 4.60±0.70 |
低剂量组 | 12 | 0.0179±0.0089 | 4.68±0.46 |
中剂量组 | 12 | 0.0220±0.0087* | 5.37±0.73* |
高剂量组 | 12 | 0.0176±0.0053* | 5.21±0.48* |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510547248.4A CN105166935B (zh) | 2015-09-01 | 2015-09-01 | 一种含有维生素d3的液体制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510547248.4A CN105166935B (zh) | 2015-09-01 | 2015-09-01 | 一种含有维生素d3的液体制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105166935A CN105166935A (zh) | 2015-12-23 |
CN105166935B true CN105166935B (zh) | 2018-08-31 |
Family
ID=54889778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510547248.4A Active CN105166935B (zh) | 2015-09-01 | 2015-09-01 | 一种含有维生素d3的液体制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105166935B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA002492B1 (ru) * | 1997-07-30 | 2002-06-27 | Менарини Интернэшнл Оперейшнз Люксембург С.А. | Фармацевтическая композиция, содержащая витамин d и кальций, способы ее приготовления и терапевтического применения |
CN1212080C (zh) * | 1999-12-09 | 2005-07-27 | Dsmip资产有限公司 | 含脂溶性维生素的组合物 |
MXPA06001706A (es) * | 2003-08-19 | 2006-05-19 | Boehringer Ingelheim Int | Jarabe multivitaminico para ninos o adultos jovenes. |
CN104367569A (zh) * | 2014-11-06 | 2015-02-25 | 江苏隆力奇生物科技股份有限公司 | 一种纳米辅酶q10口服液 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643009A (en) * | 1996-02-26 | 1997-07-01 | The Whitaker Corporation | Electrical connector having a pivot lock |
-
2015
- 2015-09-01 CN CN201510547248.4A patent/CN105166935B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA002492B1 (ru) * | 1997-07-30 | 2002-06-27 | Менарини Интернэшнл Оперейшнз Люксембург С.А. | Фармацевтическая композиция, содержащая витамин d и кальций, способы ее приготовления и терапевтического применения |
CN1212080C (zh) * | 1999-12-09 | 2005-07-27 | Dsmip资产有限公司 | 含脂溶性维生素的组合物 |
MXPA06001706A (es) * | 2003-08-19 | 2006-05-19 | Boehringer Ingelheim Int | Jarabe multivitaminico para ninos o adultos jovenes. |
CN104367569A (zh) * | 2014-11-06 | 2015-02-25 | 江苏隆力奇生物科技股份有限公司 | 一种纳米辅酶q10口服液 |
Non-Patent Citations (1)
Title |
---|
维生素C微胶囊化包埋工艺研究;李纲,等;《应用化工》;20130331;第42卷(第3期);第404-409页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105166935A (zh) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104083468B (zh) | 一种治疗男性少精弱精、提高精子质量的药物 | |
CN107319525A (zh) | 一种减肥减脂专用型临床营养配方及其制备方法 | |
CN103750339B (zh) | 雪莲培养物保健食品及其用途 | |
WO2023005265A1 (zh) | 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用 | |
CN109700011A (zh) | 一种改善睡眠的保健食品及其制备方法 | |
CN104799286B (zh) | 一种用于提高免疫力的组合物及其制备方法 | |
WO2020168948A1 (zh) | 一种即食燕窝羹及其制备方法 | |
WO2016141775A1 (zh) | 吉林人参低聚肽在制备抗疲劳的食品或保健食品中的用途 | |
WO2016141774A1 (zh) | 吉林人参低聚肽在制备改善和增强性功能的食品或保健食品中的用途 | |
CN105166935B (zh) | 一种含有维生素d3的液体制剂及其制备方法 | |
CN102552645B (zh) | 一种补肾壮阳保健药物及其制备方法 | |
US20180169071A1 (en) | Nutritional supplement composition | |
CN103933146A (zh) | 一种可调节人体免疫力的花粉制品 | |
CN104666823B (zh) | 一种调节免疫力、延缓衰老的药物组合物及其制备方法 | |
CN103798596B (zh) | 一种供心脑血管疾病患者食用的全营养配方食品 | |
Maenpuen et al. | The Effects of Lysiphyllum strychnifolium Tea on Breastmilk Volume and Nutrient Composition of Human Milk: A Randomized Controlled Trial. | |
CN113197304A (zh) | 一种改善睡眠的保健食品及其制备方法 | |
CN105595346A (zh) | 一种用于补钙的液体制剂及其制备方法 | |
CN101249236B (zh) | 一种治疗癫痫的中西医药结合制剂 | |
CN104547264A (zh) | 一种改善记忆力的胶囊及其制备方法 | |
CN109601880A (zh) | 一种增加骨密度的保健食品 | |
CN102579713B (zh) | 治疗儿童肥胖症的中药及制备方法 | |
JP6708916B1 (ja) | 補気調節用チワン族医薬品組成物及びその調製方法 | |
CN107737259A (zh) | 一种提高男性性功能的中药组方 | |
CN111202218B (zh) | 一种阿胶禽蛋及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Zhang Wei Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190507 Address after: 102446 110m north of Xiaoying Village Committee, Liangxiang Township, Fangshan District, Beijing Patentee after: Congrui Huikang (Beijing) Technology Development Co., Ltd. Address before: Room 302, Building 1, Gongxing Garden, Liangxiang, Fangshan District, Beijing Patentee before: Zhang Wei |
|
TR01 | Transfer of patent right |